SRTA · CIK 0001779128
What Strata Critical Medical, Inc. told the SEC could break it.
Strata Critical Medical's risks are concentration on nearly every side of its organ-recovery and transplant-services business. A material portion of revenue in both 2025 and 2024 came from the same single national hospital group, and its purchasing is similarly narrow, with one operating vendor accounting for about 17% of 2025 purchases. The work itself depends on scarce, hard-to-retain specialized clinicians — particularly perfusionists and organ-recovery surgeons — and on inputs largely outside its control: the availability and utilization of donor organs, transplant volumes, and adequate reimbursement and funding for organ transport.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- single national hospital group (unnamed)medium
A material portion of revenue across both 2025 and 2024 is affiliated with the same national hospital group, concentrating demand in a single customer relationship.
“Company's revenues for the years ended December 31, 2025 and 2024, respectively, are affiliated with the same national hospital group.”
SEC filing →As of 2026
Key person
- scarce clinicians — perfusionists and organ-recovery surgeonsmedium
Core surgical-recovery, NRP, organ-placement and cardiac-care offerings depend on hiring, training and retaining scarce specialized clinicians, particularly perfusionists and organ-recovery surgeons.
“Our surgical recovery, NRP, organ placement and cardiac care offerings depend on our ability to hire, train and retain clinicians, particularly perfusionists and organ recovery surgeons.”
SEC filing →As of 2026
Other disclosures
- donor-organ availability, transplant volumes & reimbursementmedium
The business depends on the availability and utilization of donor organs and transplant volumes, plus adequate reimbursement/funding for organ transport — inputs largely outside the company's control.
“our dependence on the availability and utilization of donor organs and transplant volumes; insufficient reimbursement or funding for organ transport and related services; risks inherent in organ transportation operations”
SEC filing →As of 2026
Supplier concentration
- largest operating vendor — 17% of purchases (unnamed)medium
Vendor purchasing is concentrated: one operating vendor accounted for ~17% of purchases in 2025 (two vendors were 18% and 12% in 2024), indicating reliance on a small set of unnamed suppliers.
“One vendor accounted for 17 % of the Company's purchases from operating vendors for the year ended December 31, 2025.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch